Search / Trial NCT00002209

Safety and Effectiveness of CPI-1189 in HIV-Infected Males on Combination Anti-HIV Drug Therapy

Launched by CENTAUR PHARMACEUTICALS · Aug 30, 2001

Trial Information

Current as of January 03, 2025

Completed

Keywords

Dose Response Relationship, Drug Drug Therapy, Combination Aids Dementia Complex Zidovudine Lamivudine Indinavir Reverse Transcriptase Inhibitors

ClinConnect Summary

Late-stage HIV infection can cause AIDS dementia (brain damage due to HIV leading to losses of memory and muscle control). CPI-1189 may be able to postpone AIDS dementia or slow it down.

In this randomized, double-blind study, 48 HIV-infected, otherwise healthy, male volunteers receive either multiple-dose CPI-1189 or placebo by mouth for 15 consecutive days. Each dosing group begins 6 weeks following the start of the preceding group. Volunteers enter the study site the night before dosing on Days 1 and 15 and remain at the study site for 72 hours following dosing. Throughout the study, vo...

Gender

MALE

Eligibility criteria

  • Inclusion Criteria
  • You may be eligible for this study if you:
  • Are an HIV-positive man who is otherwise in good health.
  • Are 18-50 years old.
  • Have a CD4 count of 75-500 cells/mm3.
  • Are currently taking zidovudine (ZDV), lamivudine (3TC), and indinavir (IDV).

About Centaur Pharmaceuticals

Centaur Pharmaceuticals is a leading biopharmaceutical company dedicated to advancing innovative therapies for unmet medical needs. With a strong focus on research and development, Centaur Pharmaceuticals leverages cutting-edge science and technology to create effective treatments across a range of therapeutic areas. Committed to the highest standards of clinical excellence, the company collaborates with healthcare professionals and regulatory bodies to ensure the safety and efficacy of its products. Through rigorous clinical trials and a patient-centered approach, Centaur Pharmaceuticals aims to improve patient outcomes and enhance the quality of life for individuals affected by various diseases.

Locations

Phoenix, Arizona, United States

People applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Discussion 0

Similar Trials